NEW HAVEN, Conn., Aug. 8, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and six months ended June 30, 2011. For the second quarter of 2011, Achillion reported a net loss of $11.3 million or $0.19 per share, compared with a net loss of $6.4 million or $0.17 per share for the second quarter of 2010. Cash, cash equivalents and marketable securities as of June 30, 2011 were approximately $99.6 million.
